Literature DB >> 10493889

Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies.

H Zhang1, Q Wang, K T Montone, J E Peavey, J A Drebin, M I Greene, R Murali.   

Abstract

We have studied two anti-p185 antibodies: the monoclonal antibody 7. 16.4 and rhuMAb 4D5, which were raised against the the ectodomain of rat (p185(neu)), and the human (p185(her2/neu)) homolog, respectively. Studies on the structure of these two antibodies indicate that they share structural similarity in the variable region, especially the CDR3 region, which determines the antibody-antigen interaction. Further studies by flow cytometry revealed that 7.16.4 can compete with rhuMAb4D5 for binding to the cell surface p185(her2/neu), suggesting that these two antibodies share an epitope on the p185 receptor. Furthermore, 7.16.4 can also inhibit proliferation and transformation caused by p185(her2/neu). Moreover the rhuMAb 4D5 binds to the rat p185(neu). With the observation that 7.16.4 positively stains human breast cancer tissues that overexpress p185(her2/neu), 7.16.4 may be useful for the pathological diagnosis and therapy of human tumors. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493889     DOI: 10.1006/exmp.1999.2266

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  21 in total

1.  Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer.

Authors:  Qingfei Wang; Shau-Hsuan Li; Hai Wang; Yi Xiao; Ozgur Sahin; Samuel W Brady; Ping Li; Hailiang Ge; Elizabeth M Jaffee; William J Muller; Gabriel N Hortobagyi; Dihua Yu
Journal:  Cancer Res       Date:  2012-07-06       Impact factor: 12.701

Review 2.  ErbB receptors: from oncogenes to targeted cancer therapies.

Authors:  Hongtao Zhang; Alan Berezov; Qiang Wang; Geng Zhang; Jeffrey Drebin; Ramachandran Murali; Mark I Greene
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

3.  Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.

Authors:  John Stagg; Sherene Loi; Upulie Divisekera; Shin Foong Ngiow; Helene Duret; Hideo Yagita; Michele W Teng; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

4.  Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.

Authors:  Victor A Gall; Anne V Philips; Na Qiao; Karen Clise-Dwyer; Alexander A Perakis; Mao Zhang; Guy T Clifton; Pariya Sukhumalchandra; Qing Ma; Sangeetha M Reddy; Dihua Yu; Jeffrey J Molldrem; George E Peoples; Gheath Alatrash; Elizabeth A Mittendorf
Journal:  Cancer Res       Date:  2017-08-17       Impact factor: 12.701

5.  Neuregulin-ErbB signaling promotes microglial proliferation and chemotaxis contributing to microgliosis and pain after peripheral nerve injury.

Authors:  Margarita Calvo; Ning Zhu; Christoforos Tsantoulas; Zhenzhong Ma; John Grist; Jeffrey A Loeb; David L H Bennett
Journal:  J Neurosci       Date:  2010-04-14       Impact factor: 6.167

6.  A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.

Authors:  Gang Chen; Richa Gupta; Silvia Petrik; Marina Laiko; James M Leatherman; Justin M Asquith; Maithili M Daphtary; Elizabeth Garrett-Mayer; Nancy E Davidson; Kellie Hirt; Maureen Berg; Jennifer N Uram; Tianna Dauses; John Fetting; Elizabeth M Duus; Saadet Atay-Rosenthal; Xiaobu Ye; Antonio C Wolff; Vered Stearns; Elizabeth M Jaffee; Leisha A Emens
Journal:  Cancer Immunol Res       Date:  2014-08-12       Impact factor: 11.151

7.  Tamoxifen resistance and Her2/neu expression in an aged, irradiated rat breast carcinoma model.

Authors:  Norman C Peterson; Matthew D Servinsky; Archie Christian; Zhongsheng Peng; Weiping Qiu; Jill Mann; John Dicello; David L Huso
Journal:  Carcinogenesis       Date:  2005-04-28       Impact factor: 4.944

8.  Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.

Authors:  Ozgur Sahin; Qingfei Wang; Samuel W Brady; Kenneth Ellis; Hai Wang; Chia-Chi Chang; Qingling Zhang; Preety Priya; Rui Zhu; Stephen T Wong; Melissa D Landis; William J Muller; Francisco J Esteva; Jenny Chang; Dihua Yu
Journal:  Cell Res       Date:  2014-03-28       Impact factor: 25.617

9.  Disabling of the erbB Pathway Followed by IFN-γ Modifies Phenotype and Enhances Genotoxic Eradication of Breast Tumors.

Authors:  Yasuhiro Nagai; Hiromichi Tsuchiya; E Aaron Runkle; Peter D Young; Mei Q Ji; Larry Norton; Jeffrey A Drebin; Hongtao Zhang; Mark I Greene
Journal:  Cell Rep       Date:  2015-09-10       Impact factor: 9.423

10.  scFv-based "Grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors.

Authors:  Zheng Cai; Ting Fu; Yasuhiro Nagai; Lian Lam; Marla Yee; Zhiqiang Zhu; Hongtao Zhang
Journal:  Cancer Res       Date:  2013-02-08       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.